Drug Profile
Selatogrel - Idorsia Pharmaceuticals
Alternative Names: ACT-246475Latest Information Update: 01 Mar 2024
Price :
$50
*
At a glance
- Originator Actelion Pharmaceuticals
- Developer Idorsia Pharmaceuticals
- Class Anti-ischaemics; Antiplatelets; Antithrombotics; Cardiovascular therapies; Piperazines; Pyrimidines; Pyrrolidines; Small molecules; Vascular disorder therapies
- Mechanism of Action Purinoceptor P2Y12 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Myocardial infarction
- Phase II Acute coronary syndromes
- No development reported Cardiovascular disorders; Coronary artery disease
Most Recent Events
- 28 Feb 2024 Viatris and Idorsia entered into licensing agreement for the development and commercialisation of two phase III assets of selatogrel
- 28 Mar 2023 No recent reports of development identified for phase-I development in Coronary artery disease(In volunteers) in Germany (SC, Injection)
- 24 May 2022 Antares Pharma has been acquired by Halozyme Therapeutics